Brief: Neurizon Therapeutics Gets EMA's Positive Opinion On Orphan Medicinal Product Designation For NUZ-001
11/11/2024 07:16
Nov 11 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX :
* NEURIZON THERAPEUTICS RECEIVES POSITIVE OPINION ON ORPHAN MEDICINAL
PRODUCT
DESIGNATION FOR NUZ-001 IN EUROPE
Source text: ID:nPreGmh0Xa
Further company coverage: NUZ.AX
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon Therapeutics jumps on deal with US firm
Brief: Neurizon Therapeutics Executes Long-Term Supply Agreement With Elanco
Brief: Neurizon Therapeutics Receives Ethics Approval For Phase 1 Nuz-001 Oral Liquid Formulation Study
Brief: Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 Million
Brief: Neurizon Therapeutics Says Michael Thurn Resigns As Managing Director And CEO